Cambrex Corp. Trading 3.8% Higher Following Better-Than-Expected Earnings (CBM)
Cambrex Corp. (NYSE:CBM) traded up 3.8% on Wednesday following a stronger than expected earnings report, Stock Ratings Network.com reports. The company traded as high as $21.73 and last traded at $21.70, with a volume of 159,480 shares traded. The stock had previously closed at $20.90.
The company reported $0.32 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.21 by $0.11.
Several analysts have recently commented on the stock. Analysts at Zacks upgraded shares of Cambrex Corp. from a “neutral” rating to an “outperform” rating in a research note on Monday. They now have a $23.20 price target on the stock. Separately, analysts at First Analysis downgraded shares of Cambrex Corp. from an “overweight” rating to an “equal weight” rating in a research note on Friday, August 8th. Finally, analysts at Longbow Research raised their price target on shares of Cambrex Corp. to $27.00 in a research note on Tuesday, August 5th. They now have a “buy” rating on the stock.
In other Cambrex Corp. news, SVP William M. Haskel unloaded 28,100 shares of Cambrex Corp. stock on the open market in a transaction dated Thursday, August 7th. The shares were sold at an average price of $22.50, for a total transaction of $632,250.00. The sale was disclosed in a legal filing with the SEC, which is available at this link.
The stock has a 50-day moving average of $21.45 and a 200-day moving average of $20.45. The company has a market cap of $667.9 million and a P/E ratio of 19.61.
Cambrex Corporation (NYSE:CBM) is a life sciences company, which provides products and services, which accelerate and improve the development and commercialization of new and generic therapeutics.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.